Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc. (PARD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pard · pe ratio · data through Dec 31, 2010
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Poniard Pharmaceuticals, Inc. (PARD) measures how much investors pay for each dollar of the company's trailing earnings. PARD's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$25.65.
Source: FMP · /ratios-ttm · /analyst-estimates · 2010-12-31
PE Ratio History
1991 – 2010 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Poniard Pharmaceuticals, Inc.You PARD | $0M | N/A | — | -$25.65 |
 Aeolus Pharmaceuticals, Inc. AOLS | $0M | N/A | — | -$0.02 |
 Strategic Partners A/S OZYMF | $4M | N/A | — | -$20.59 |
 PaxMedica, Inc. Common Stock PXMD | $0M | N/A | — | -$11.00 |
 Q BioMed Inc. QBIO | $0M | N/A | — | -$0.05 |
 RenovaCare, Inc. RCAR | $0M | N/A | — | -$0.05 |
 Regenicin, Inc. RGIN | $0M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2010-12-31Latest FY2010 | — | $-25.65 | — | |
2009-12-31 FY2009 | — | $-51.84 | — | |
2008-12-31 FY2008 | — | $-56.01 | — | |
2007-12-31 FY2007 | — | $-42.63 | — | |
2006-12-31 FY2006 | — | $-53.62 | — | |
2005-12-31 FY2005 | — | $-149.68 | — | |
2004-12-31 FY2004 | — | $-154.20 | — | |
2003-12-31 FY2003 | — | $-44.50 | — | |
2002-12-31 FY2002 | — | $-207.96 | — | |
2001-12-31 FY2001 | — | $-216.32 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Poniard Pharmaceuticals, Inc. (PARD) measures how much investors pay for each dollar of the company's trailing earnings. PARD's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$25.65.
Frequently asked questions
PARD pe ratio · 6 questionsPARD's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$25.65. Data sourced from Financial Modeling Prep via PARD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Poniard Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09